Clinical Trial Update: To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of KP104 [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating KP104 for safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy in Paroxysmal nocturnal hemoglobinuria; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• KP104 (KP104)

Snippet

Sponsor: Kira Pharmacenticals (US), LLC. | Conditions: Paroxysmal Nocturnal Hemoglobinuria | Phase 2 | Status: ACTIVE_NOT_RECRUITING